Ubisoft’s shares look beaten down after a big reset, but a recent Tencent deal suggests its biggest game brands may be worth far more than the market is giving them credit for. The catch is whether heavy losses, tight control by insiders, and staff unrest stop the company from ever turning those assets into value for shareholders.Read more

The U.S. is scrambling to secure a key metal used in defense and new kinds of batteries, and NevGold says it has an easier-to-mine source sitting close to the surface in the American West. The catch is that the big proof point is still coming, and whether upcoming results deliver could make or break the story.Read more

Vulcan Minerals looks like a small resource company, but much of what you pay today is backed by cash and a large stake in a separate salt developer, leaving its other assets seemingly ignored. The bigger story is a royalty tied to future salt production that could bring in steady cash while the company also keeps optional upside from hydrogen storage and new drilling targets.Read more

Atlas Salt is building a new underground salt mine near a port in Newfoundland, aiming to supply a steady, everyday product that cities rely on year after year. The big question is whether the company can lock in the funding to finish construction—because if it does, the market may have to rethink how risky this project really is.Read more

Berkshire Hathaway leans on a huge cash pile, low debt, and a long history of patient deal-making to hold up through rough markets and pounce on opportunities. The bigger question now is whether the handoff from Warren Buffett to Greg Abel keeps that steady approach working as the world changes.Read more

01 Quantum Inc. (formerly 01 Communique) has spent nearly a decade in quiet R&D, positioning itself as a first-to-market provider of software designed to protect the digital world from the existential threat of quantum computers.Read more

QuantumScape aims to make electric car batteries that can charge much faster, last longer, and be safer, using a new ceramic-based design that could change what drivers expect from an EV. The big question is whether it can reliably scale this lab-proven tech into mass production through its Volkswagen partnership before rivals catch up.Read more

Beam Therapeutics is betting that a newer, more precise form of gene editing can fix genetic diseases without the DNA damage risks tied to older approaches. Early human results in a liver-targeted program, plus a push to remove harsh chemotherapy from stem cell transplants, could open much larger patient groups—but competition and clinical execution still matter.Read more

IonQ claims it has crossed a key technical hurdle and now has the resources to push from lab promise toward real-world quantum machines. The big question is whether its room‑temperature approach and recent buyouts can turn into large deals with tech giants—or whether execution stumbles derail the story.Read more